Want to see LYRA full AI Analyst Report?
Lyra Therapeutics (LYRA) AI Stock Analysis
Lyra Therapeutics
(Other OTC:LYRA)
The score is primarily constrained by weak financial performance (minimal and declining revenue, persistent losses, ongoing cash burn, and negative equity), which elevates financing risk. Technicals are mixed-to-weak with a negative MACD and the stock below longer-term averages despite neutral RSI. Valuation support is limited due to negative earnings (negative P/E) and no dividend yield.
Lyra Therapeutics (LYRA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $337.23K
- Dividend Yield
- ―
- Average Volume (3M)
- 1,632
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 4.79
- Revenue Growth
- -74.05%
- EPS Growth
- 73.08%
- Country
- US
- Employees
- 27
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Lyra Therapeutics Business Overview & Revenue Model
Company Description
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique tech...
How the Company Makes Money
As a clinical-stage biotechnology company, Lyra Therapeutics has historically not generated material recurring revenue from commercial product sales because it does not have widely disclosed, ongoing marketed products. Therefore, its ability to fund...
Lyra Therapeutics Financial Statement Overview
Summary
Income statement, balance sheet, and cash flow quality are weak: revenue is very small and declined sharply in 2025, profitability remains deeply negative, and cash flow is consistently negative. Losses and operating cash outflow improved in 2025 versus 2024, but negative stockholders’ equity and elevated debt relative to assets increase financial risk and ongoing reliance on external funding.
Income Statement
18Very NegativeBalance Sheet
22NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 398.00K | 398.00K | 1.53M | 1.56M | 1.36M | 285.00K |
| Gross Profit | 398.00K | 398.00K | 1.53M | 1.56M | 1.36M | -29.41M |
| EBITDA | -27.83M | -29.09M | -60.26M | -65.25M | -53.92M | -42.61M |
| Net Income | -28.92M | -28.92M | -93.44M | -62.68M | -55.28M | -43.51M |
Balance Sheet | ||||||
| Total Assets | 36.11M | 36.11M | 66.35M | 142.60M | 109.97M | 54.87M |
| Cash, Cash Equivalents and Short-Term Investments | 15.89M | 15.89M | 40.58M | 102.75M | 97.89M | 45.75M |
| Total Debt | 30.26M | 30.26M | 34.38M | 26.88M | 4.18M | 1.45M |
| Total Liabilities | 46.83M | 46.83M | 54.75M | 53.18M | 29.21M | 20.55M |
| Stockholders Equity | -10.72M | -10.72M | 11.59M | 89.42M | 80.75M | 34.32M |
Cash Flow | ||||||
| Free Cash Flow | -28.98M | -28.98M | -72.35M | -64.35M | -43.55M | -29.20M |
| Operating Cash Flow | -28.86M | -28.86M | -70.01M | -63.30M | -43.38M | -25.82M |
| Investing Cash Flow | -98.00K | -98.00K | 80.31M | -12.58M | -65.01M | -3.38M |
| Financing Cash Flow | 4.27M | 4.27M | 8.53M | 65.69M | 96.26M | 359.00K |
Lyra Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYRA, the sentiment is Negative. The current price of 0.19 is above the 20-day moving average (MA) of 0.19, above the 50-day MA of 0.17, and below the 200-day MA of 0.78, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 50.09 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LYRA.
Lyra Therapeutics Risk Analysis
Lyra Therapeutics disclosed 24 risk factors in its most recent earnings report. Lyra Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskLyra Therapeutics Peers Comparison
Overall Rating
RNAZ49Neutral
MBIO43Neutral
SLXN42Neutral- LYRA41Neutral
BOLT40Underperform
XTLB39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| RNAZ | 49Neutral | $27.60M | -0.03 | -58.08% | ― | ― | 86.74% |
| MBIO | 43Neutral | $3.14M | -0.91 | -34.23% | ― | ― | 85.52% |
| SLXN | 42Neutral | $2.26M | -0.00 | -563.11% | ― | ― | 98.10% |
| LYRA | 41Neutral | $337.23K | -0.01 | 455.31% | ― | -74.05% | 73.08% |
| BOLT | 40Underperform | $12.02M | -0.41 | -126.23% | ― | 12.79% | 37.93% |
| XTLB | 39Underperform | $7.51M | -0.55 | -269.02% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LYRA | Lyra Therapeutics, Inc. | 0.19 | -5.43 | -96.62% | |
| XTLB | XTL Biopharmaceuticals Ltd. Sponsored ADR | 1.73 | -2.48 | -58.93% | |
| MBIO | Mustang Bio | 0.41 | -0.91 | -69.02% | |
| BOLT | Bolt Biotherapeutics, Inc. | 6.57 | 1.70 | 34.91% | |
| RNAZ | Transcode Therapeutics, Inc. | 1.57 | -8.00 | -83.59% | |
| SLXN | Silexion Therapeutics Corp | 0.15 | -29.75 | -99.49% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 09, 2026